Teva Pharmaceutical Industries Limited
TEVJF
$28.36
-$4.48-13.64%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 10.85% | 53.55% | 31.78% | 198.62% | 50.34% |
| Total Depreciation and Amortization | 4.42% | -0.80% | 2.87% | -9.29% | 3.86% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -23.79% | 726.67% | -78.10% | -82.16% | 38.63% |
| Change in Net Operating Assets | 140.82% | -66.96% | 52.00% | -185.71% | -177.29% |
| Cash from Operations | 213.82% | 62.56% | 316.19% | -118.26% | -17.03% |
| Capital Expenditure | -4.41% | -41.67% | 24.41% | 1.55% | 12.84% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -100.00% | -11.11% | -47.06% | 325.00% | -89.47% |
| Other Investing Activities | 16.73% | -18.58% | 3.86% | -4.89% | -13.49% |
| Cash from Investing | 22.22% | -42.80% | 17.41% | -0.50% | -24.63% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 80.39% | -68.13% | -99.71% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2,100.00% | -300.00% | 100.27% | -3,518.18% | -- |
| Cash from Financing | 108.83% | -7,650.00% | 100.34% | -158.75% | -- |
| Foreign Exchange rate Adjustments | -11.11% | -80.00% | -111.11% | 137.19% | -221.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,121.43% | -90.95% | 128.95% | -8,805.56% | -101.70% |